EA201890893A1 - Способы лечения повреждений или состояний, относящихся к отеку цнс - Google Patents

Способы лечения повреждений или состояний, относящихся к отеку цнс

Info

Publication number
EA201890893A1
EA201890893A1 EA201890893A EA201890893A EA201890893A1 EA 201890893 A1 EA201890893 A1 EA 201890893A1 EA 201890893 A EA201890893 A EA 201890893A EA 201890893 A EA201890893 A EA 201890893A EA 201890893 A1 EA201890893 A1 EA 201890893A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cns
treatment
damage
reducing
conditions
Prior art date
Application number
EA201890893A
Other languages
English (en)
Russian (ru)
Inventor
Свен Мартин Якобсон
Original Assignee
БАЙОДЖЕН ЧЕСАПИК ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БАЙОДЖЕН ЧЕСАПИК ЭлЭлСи filed Critical БАЙОДЖЕН ЧЕСАПИК ЭлЭлСи
Publication of EA201890893A1 publication Critical patent/EA201890893A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EA201890893A 2015-10-07 2016-10-07 Способы лечения повреждений или состояний, относящихся к отеку цнс EA201890893A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (1)

Publication Number Publication Date
EA201890893A1 true EA201890893A1 (ru) 2018-09-28

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890893A EA201890893A1 (ru) 2015-10-07 2016-10-07 Способы лечения повреждений или состояний, относящихся к отеку цнс

Country Status (15)

Country Link
US (4) US20180280325A1 (cg-RX-API-DMAC7.html)
EP (1) EP3359162B1 (cg-RX-API-DMAC7.html)
JP (5) JP7349786B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240105519A (cg-RX-API-DMAC7.html)
CN (2) CN108348534A (cg-RX-API-DMAC7.html)
AU (3) AU2016335767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018006925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001321A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890893A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940669T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257542A1 (cg-RX-API-DMAC7.html)
IL (1) IL258509B2 (cg-RX-API-DMAC7.html)
MA (1) MA45574A (cg-RX-API-DMAC7.html)
MX (1) MX392466B (cg-RX-API-DMAC7.html)
WO (1) WO2017062765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
JP2022531312A (ja) * 2019-05-02 2022-07-06 バイオジェン チェサピーク エルエルシー 中枢神経系挫傷に苦しむ対象の治療方法
CN120004770A (zh) * 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) * 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
ES2807274T3 (es) * 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
CA2806069C (en) * 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
KR20240105519A (ko) 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Also Published As

Publication number Publication date
BR112018006925A2 (pt) 2018-10-16
IL258509B2 (en) 2023-04-01
US20180280325A1 (en) 2018-10-04
KR20240105519A (ko) 2024-07-05
CN108348534A (zh) 2018-07-31
AU2025202620A1 (en) 2025-05-01
US20250017880A1 (en) 2025-01-16
JP7592768B2 (ja) 2024-12-02
JP7810762B2 (ja) 2026-02-03
ES2940669T3 (es) 2023-05-10
HK1257542A1 (zh) 2019-10-25
CA3001321A1 (en) 2017-04-13
JP2026069546A (ja) 2026-04-23
US11951085B2 (en) 2024-04-09
MA45574A (fr) 2019-05-15
MX392466B (es) 2025-03-24
KR20180063296A (ko) 2018-06-11
AU2016335767A8 (en) 2018-06-28
EP3359162A4 (en) 2019-08-28
KR102681027B1 (ko) 2024-07-02
JP2018530564A (ja) 2018-10-18
AU2022279369B2 (en) 2025-02-13
US20240216309A1 (en) 2024-07-04
IL258509B (en) 2022-12-01
JP2021073317A (ja) 2021-05-13
CN115737816A (zh) 2023-03-07
US20220125750A1 (en) 2022-04-28
EP3359162B1 (en) 2022-12-21
AU2022279369A1 (en) 2023-01-19
JP2024164167A (ja) 2024-11-26
AU2016335767B2 (en) 2022-10-06
KR20260093449A (ko) 2026-06-19
JP7349786B2 (ja) 2023-09-25
JP2023053274A (ja) 2023-04-12
WO2017062765A1 (en) 2017-04-13
EP3359162A1 (en) 2018-08-15
MX2018004286A (es) 2018-08-09
AU2016335767A1 (en) 2018-05-24
IL258509A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
AU2016335767A8 (en) Methods of treating injuries or conditions related to CNS edema
PH12021552497A1 (en) Enzyme inhibitors
EA201890059A1 (ru) Ингибиторы hpk1 и способы их применения
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
EP4616902A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
MX378283B (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
PH12015502549B1 (en) Heterocyclic derivatives
MX2017007478A (es) Compuestos inhibidores.
BR112015013123A2 (pt) inibidores de beta-lactamase
UA114090C2 (uk) Сполуки, що інгібують металоферменти
EA201490088A1 (ru) Соединения, ингибирующие металлоферменты
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
EA201491385A1 (ru) Соединения, ингибирующие металлоферменты
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201791644A1 (ru) Ингибиторы mir-92 и их применение
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MY181808A (en) Method for the treatment of fibrotic disease
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.